Clinical Trials In Fargo

Discover hundreds of clinical trials in Fargo.
Search clinical trials in Fargo by condition or phase.

Filter

Filter results

Results: 187

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Fargo, Detroit Lakes, Fergus Falls, Fosstonshow 351 more

Code:

NCT03866382

Conditions

Bladder Adenocarcinoma

Bladder Clear Cell Adenocarcinoma

Bladder Mixed Adenocarcinoma

Bladder Neuroendocrine Carcinoma

Bladder Small Cell Neuroendocrine Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Scan

Cabozantinib S-malate

Computed Tomography

Echocardiography

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Fargo, Bemidji, Bismarck, Coon Rapidsshow 30 more

Code:

NCT05001880

Conditions

Peritoneal Malignant Mesothelioma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Atezolizumab

Bevacizumab

Biospecimen Collection

Carboplatin

Computed Tomography

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

Recruiting

Sponsor:

NRG Oncology

Location:

Fargo, Detroit Lakes, Fergus Falls, Fosstonshow 117 more

Code:

NCT05080673

Conditions

Adenocarcinoma of the Colon

Adenocarcinoma of the Rectum

Eligibility Criteria

Sex: All

Age: 50 - 70

Healthy Volunteers: Not accepted

Interventions

5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Fargo, Winnipeg, Sioux Falls, Rochestershow 64 more

Code:

NCT03486873

Conditions

Solid Tumors

Hematologic Malignancies

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Standard of Care (SOC)

Lenvatinib

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Recruiting

PHASE3

Sponsor:

AbbVie

Location:

Fargo, Rochester, Milwaukee, Gurneeshow 62 more

Code:

NCT06063967

Conditions

Crohn's Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Risankizumab SC

Placebo for risankizumab

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Fargo, Bemidji, Bismarck, Sioux Fallsshow 97 more

Code:

NCT04671667

Conditions

Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Hypopharyngeal Squamous Cell Carcinoma

Recurrent Laryngeal Squamous Cell Carcinoma

Recurrent Oral Cavity Squamous Cell Carcinoma

Recurrent Oropharyngeal Squamous Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Cisplatin

Computed Tomography

Intensity-Modulated Radiation Therapy

Magnetic Resonance Imaging

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

Recruiting

Sponsor:

Vertos Medical, Inc.

Location:

Fargo, Grand Forks, Alexandria, Sartellshow 941 more

Code:

NCT03072927

Conditions

Lumbar Spinal Stenosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MILD

Interspinous Process Decompression

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Recruiting

PHASE3

Sponsor:

Sanofi

Location:

Fargo, Plymouth, Iowa City, Milwaukeeshow 75 more

Code:

NCT06141473

Conditions

Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Frexalimab

Teriflunomide

Placebo infusion

Placebo tablet

MRI contrast-enhancing agents

Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12

Recruiting

Sponsor:

Essentia Health

Location:

Fargo, Detroit Lakes, Fosston, Park Rapidsshow 12 more

Code:

NCT05454189

Conditions

Maintenance of Implanted Port Devices

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Reduced IPD Flush Schedule

Standard IPD Flush Schedule

A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

Recruiting

PHASE3

Sponsor:

Melt Pharmaceuticals

Location:

Fargo, W. Fargo, Alexandria, Sioux Fallsshow 8 more

Code:

NCT06383273

Conditions

Cataract

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

MELT-300 sublingual tablet

Midalozam sublingual tablet

Placebo sublingual tablet